CD8A and glioblastoma: Given the heterogeneous, immunosuppressive nature of GBM and its documented influence on immunotherapy response 23, 56, 61, we hypothesized that heterogeneity in distribution of the CD8+ immune population in the brain would be associated with downstream therapeutic benefit.